Skip to Content
Merck
  • Splicing inhibition decreases phosphorylation level of Ser2 in Pol II CTD.

Splicing inhibition decreases phosphorylation level of Ser2 in Pol II CTD.

Nucleic acids research (2015-07-24)
Mitsunori Koga, Megumi Hayashi, Daisuke Kaida
ABSTRACT

Phosphorylation of the C-terminal domain of the largest subunit of RNA polymerase II (Pol II), especially Ser2 and Ser5 residues, plays important roles in transcription and mRNA processing, including 5' end capping, splicing and 3' end processing. These phosphorylation events stimulate mRNA processing, however, it is not clear whether splicing activity affects the phosphorylation status of Pol II. In this study, we found that splicing inhibition by potent splicing inhibitors spliceostatin A (SSA) and pladienolide B or by antisense oligos against snRNAs decreased phospho-Ser2 level, but had little or no effects on phospho-Ser5 level. In contrast, transcription and translation inhibitors did not decrease phospho-Ser2 level, therefore inhibition of not all the gene expression processes cause the decrease of phospho-Ser2. SSA treatment caused early dissociation of Pol II and decrease in phospho-Ser2 level of chromatin-bound Pol II, suggesting that splicing inhibition causes downregulation of phospho-Ser2 through at least these two mechanisms.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Anti-RNA polymerase II subunit B1 (phospho CTD Ser-2) Antibody, clone 3E10, clone 3E10, from rat
Sigma-Aldrich
Anti-RNA polymerase II subunit B1 (phospho-CTD Ser-5) Antibody, clone 3E8, clone 3E8, from rat
Sigma-Aldrich
Monoclonal Anti-α-Tubulin antibody produced in mouse, ascites fluid, clone B-5-1-2